Cargando…

Highly innovative drugs in the Czech Republic: retrospective analysis of impact on early market entry, regular reimbursement system entry and public pharmaceutical expenditure

Detalles Bibliográficos
Autores principales:	Lukačišinová, Anna, Skácelová, Helena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603333/ http://dx.doi.org/10.1186/2052-3211-8-S1-O3

Ejemplares similares

Managed entry agreements
por: Muscolo, Luisa AA, et al.
Publicado: (2014)

Adapting pharmaceutical reimbursement policies to manage spending on high-priced drugs
por: Docteur, Elizabeth, et al.
Publicado: (2015)

HIV, cyclophilins and nuclear entry: going under the radar
por: Towers, Greg
Publicado: (2011)

A framework for assessing the impact of pharmaceutical reimbursement policies on incentives to innovate
por: Docteur, Elizabeth, et al.
Publicado: (2015)

Entry inhibitors as topical microbicides to prevent HIV-1 sexual transmission
por: Moore, John P
Publicado: (2006)

HIV entry blocked by maraviroc can cause an overestimation of viral load
por: Sloan, RD, et al.
Publicado: (2010)

OA011-02. Defining the mechanisms of HIV entry and interactions with the female genital tract
por: Carias, AM, et al.
Publicado: (2009)

Combined on- and off-site training contributes to strengthening the unified pharmaceutical system in the Dominican Republic
por: Barillas, Edgar, et al.
Publicado: (2014)

Expenditures on Mental Health Care in the Czech Republic in 2015
por: Broulikova, Hana M., et al.
Publicado: (2019)

GMP-mediated regulation of cardiovascular Ca(2+ )entry channel TRPC6 and its pathophysiological implications
por: Inoue, Ryuji, et al.
Publicado: (2009)

Different routes of entry of HTLV-1 during infection of primary dendritic cells and CD4+ T cells
por: Jones, Kathryn S, et al.
Publicado: (2014)

Lv4, an activity that restricts nuclear entry of SIV(MAC)/SIV(SM) in human blood cells
por: Pizzato, Massimo, et al.
Publicado: (2013)

The effect of reimbursement on MRgFUS treatment of uterine fibroids
por: Machtinger, Ronit, et al.
Publicado: (2015)

Reimbursement of orphan drugs: the Pompe and Fabry case in the Netherlands
por: van den Brink, Rinke
Publicado: (2014)

Impact of DRG reimbursement system on hospital efficiency: systematic review
por: Tabrizi, Hossein Moshiri
Publicado: (2012)

Approval, reimbursement and pricing of high-cost cancer medicines in Australia
por: Vitry, Agnes
Publicado: (2015)

Regional Innovation Systems Analysis and Evaluation: The Case of the Czech Republic
por: Stejskal, Jan, et al.
Publicado: (2017)

An unprecedented and simple gp120 switch mechanism enables HIV-1 to overcome multiple entry inhibitors and tropism limitations
por: Platt, Emily, et al.
Publicado: (2006)

PI3K-C2α regulates Polycystin-2 ciliary entry to prevent kidney cyst formation
por: Margaria, JP, et al.
Publicado: (2015)

Introduction of generic substitution and reference pricing in Ireland: early effects on state pharmaceutical expenditure and generic penetration, and associated success factors
por: Spillane, Susan, et al.
Publicado: (2015)

Paying for Outcomes: Innovative Coverage and Reimbursement Schemes for Pharmaceuticals
por: Carlson, Josh, et al.
Publicado: (2009)

Pharmaceutical pricing and reimbursement policies: perspectives for the future
por: Gray, Andrew L
Publicado: (2015)

Adoption of an infection prevention and control programme (IPCP) in the Republic of Kiribati: a case study in diffusion of innovations theory
por: Zimmerman, P-A, et al.
Publicado: (2011)

Reimbursement categories as a way of allocating measures and monitoring expenditures on medicines
por: Lipińska, Aneta, et al.
Publicado: (2015)

Factors associated with loss to follow up after entry into care of HIV infected children ineligible for antiretroviral therapy: data from an HIV cohort study in India
por: Naik, Praveen Kumar, et al.
Publicado: (2014)

The HIV-2 Vpx protein usurps the Cul4A-DDB1-DCAF1 ubiquitin ligase to overcome a post-entry block in macrophage infection
por: Ayinde, Diana, et al.
Publicado: (2009)

The Impact of Reimbursement Practices on the Pharmaceutical Market for Off-Patent Medicines in Slovakia
por: Tesar, Tomas, et al.
Publicado: (2021)

Health economic value of an innovation: delimiting the scope and framework of future market entry agreements
por: Launois, Robert, et al.
Publicado: (2014)

Proposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry
por: Badora, Karolina, et al.
Publicado: (2017)

Adapting a trial design based on feasibility of recruitment where several treatment groups are possible and the outcome is long-term: pre-empt flexible-entry internal pilot study
por: Middleton, Lee, et al.
Publicado: (2015)

Data entry checking - is it necessary?
por: McPherson, Gladys
Publicado: (2013)

Public expenditure on road safety policy and programmes: right or wrong direction to achieve the decade of action on road safety goal in Thailand
por: Phanthunane, Pudtan, et al.
Publicado: (2014)

PFAPA syndrome in the Czech Republic: a single-centre experience
por: Król, Petra, et al.
Publicado: (2012)

Budget Impact of Publicly Reimbursed Prescription Medicines in the Republic of Srpska
por: Petrusic, Tamara, et al.
Publicado: (2015)

Medicare risk contracting: Determinants of market entry
por: Porell, Frank W., et al.
Publicado: (1990)

The impact of billing/reimbursement structures on the integration of aSBI into primary care practice: implementation experiences at five different types of clinics
por: Hartje, Joyce, et al.
Publicado: (2015)

Val50Ala variant of familial amyloid neuropathy – a rare case in the Czech Republic
por: Pika, Tomas, et al.
Publicado: (2015)

OAB-046: COVID-19 infection in multiple myeloma patients – retrospective analysis of 371 Czech patients
por: Radocha, Jakub, et al.
Publicado: (2021)

The impact of Ghana's National Health Insurance Scheme median pharmaceutical pricing methodology and reimbursement policy on the pharmaceutical system
por: Mordi, Dumebi O, et al.
Publicado: (2015)

Price and reimbursement for orphan medicines and managed entry agreements: does Italy need a framework?
por: Jommi, Claudio, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mace2cdi1jnr3n87fio03mfni1